Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk.

Titel:: Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk.
Dokumenttyp:: Journal Article; Research Support, Non-U.S. Gov't
Autor(en):: Weingold, Robert; Zinman, Bernard; Mattheus, Michaela; Ofstad, Anne Pernille; Steubl, Dominik; Wanner, Christoph; Inzucchi, Silvio E
Abstract:: T2D is a well-established risk factor for development and progression of CKD. KDIGO recommends categorization of risk by likelihood of progression to ESKD. Compared to placebo, empagliflozin decreases likelihood of worsening (OR 0.70, 95 % CI 0.62-0.78) and increases likelihood of improvement (OR 1.56, 95 % CI 1.30-1.86) in KDIGO risk category.
Zeitschriftentitel:: J Diabetes Complications
Jahr:: 2023
Band / Volume:: 37
Heft / Issue:: 11
Volltext / DOI:: doi:10.1016/j.jdiacomp.2023.108628
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/37852075
Print-ISSN:: 1056-8727
TUM Einrichtung:: Professur für Nephrologie (Prof. Heemann)
BibTeX

Vorkommen: